Company profile: Annexin Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biotechnology focused on Annexin A5-based therapeutics. Develops ANXV, a human recombinant Annexin A5 that targets phosphatidylserine for acute treatment of cardiovascular diseases and is being investigated for retinal vein occlusion, cancer, and sickle cell disease. ANXV aims to protect cells, modulate immune responses, and reduce vascular inflammation and cellular stress.
Products and services
- ANXV: recombinant drug candidate containing the human protein Annexin A5 that targets phosphatidylserine to protect cells and modulate immune responses in RVO, cancer, and other diseases
- Cardiovascular Disease Treatment: investigational ANXV therapy targeting phosphatidylserine to reduce inflammation and cellular stress in blood vessels for acute treatment of patients with cardiovascular injuries
- Retinal Vein Occlusion (RVO) Treatment: ophthalmic ANXV use targeting phosphatidylserine to address vein blockages in the eye that risk significant vision impairment or blindness
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Annexin Pharmaceuticals
EBR Systems
HQ: United States
Website
- Description: Provider of wireless cardiac pacing solutions, including the WiSE CRT System for cardiac resynchronization therapy that delivers stimulation directly to the inside of the left ventricle and is designed to overcome limitations of existing CRT systems, leveraging proprietary WiSE Technology for wireless tissue stimulation that eliminates the need for a left-ventricle lead.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EBR Systems company profile →
Cormatrix Cardiovascular
HQ: United States
Website
- Description: Provider of biomaterial medical devices that harness the body’s ability to repair damaged heart tissue, including the CorTricuspid ECM Valve for surgical management of tricuspid valve disease in adult and pediatric patients, and the FDA-cleared CorPatch epicardial repair product for supporting and repairing heart areas weakened after myocardial infarction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cormatrix Cardiovascular company profile →
Myocor
HQ: United States
Website
- Description: Provider of therapeutic cardiac technologies and evaluations to treat mitral regurgitation and heart failure, improving cardiac function. Offers the Coapsys System, a device and therapy for mitral valve insufficiency via a less invasive, off-pump, closed-heart procedure. Founded in 1996 and based in Minnesota.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myocor company profile →
Cephea
HQ: United States
Website
- Description: Provider of catheter-delivered mitral valve regurgitation products and heart valves for the treatment of coronary artery disease, offering catheter-based therapies including balloons and stents for aortic valve replacements. Incorporated in 2011 and based in San Jose, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cephea company profile →
Micro Interventional Devices
HQ: United States
Website
- Description: Provider of percutaneous and minimally invasive structural heart repair technologies, including PolyCor polymeric anchors for soft-tissue cardiac applications; the MIA-T and MIA-M percutaneous annuloplasty systems for tricuspid and mitral valve regurgitation; and the Transcatheter Cardiac Repair platform enabling catheter-based treatment of structural heart disease without cardiopulmonary bypass.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micro Interventional Devices company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Annexin Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Annexin Pharmaceuticals
2.2 - Growth funds investing in similar companies to Annexin Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Annexin Pharmaceuticals
4.2 - Public trading comparable groups for Annexin Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →